Tempus AI (NASDAQ:TEM) Trading Up 8.3% After Analyst Upgrade

Tempus AI, Inc. (NASDAQ:TEM)’s stock price traded up 8.3% on Friday after BTIG Research raised their price target on the stock from $70.00 to $80.00. BTIG Research currently has a buy rating on the stock. Tempus AI traded as high as $72.62 and last traded at $72.21. Approximately 9,425,782 shares were traded during trading, an increase of 58% from the average daily volume of 5,961,162 shares. The stock had previously closed at $66.65.

A number of other brokerages have also weighed in on TEM. TD Cowen reissued a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Piper Sandler cut their price objective on Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a report on Tuesday, August 4th. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Stifel Nicolaus cut their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a report on Monday, August 3rd. Finally, Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $65.69.

Insider Buying and Selling

In other Tempus AI news, CFO James William Rogers sold 26,313 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the sale, the chief financial officer owned 106,024 shares in the company, valued at approximately $6,361,440. This represents a 19.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the sale, the executive vice president directly owned 146,067 shares in the company, valued at $7,246,383.87. The trade was a 13.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 943,202 shares of company stock worth $46,417,587. Corporate insiders own 24.26% of the company’s stock.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Investor enthusiasm has continued following reported progress in the Merck–Moderna cancer-vaccine program. Although the development is not directly attributable to Tempus, it reinforces the potential value of genomic data and precision-oncology platforms—areas central to Tempus’ strategy. Tempus AI stock move
• Positive Sentiment: BTIG Research raised its Tempus price target from $70 to $80 and maintained a “Buy” rating. The upgrade provides a fresh Wall Street catalyst and suggests analysts see additional upside after the recent advance. BTIG raises Tempus AI price target
• Positive Sentiment: Tempus’ planned approximately $1.5 billion all-stock acquisition of Personalis is attracting investor attention. The deal would add genomic-data and cancer-testing capabilities, potentially strengthening Tempus’ drug-development and precision-medicine platform. Tempus AI biotech deal
• Positive Sentiment: Trading activity has been supportive: call-option volume was reported at roughly 40,671 contracts, well above normal levels. That indicates bullish speculation and may be amplifying the stock’s momentum.
• Neutral Sentiment: The move above key moving averages has been characterized as a possible short squeeze. This can extend gains, but it also increases the risk of sharp reversals and continued volatility. Tempus AI technical rally
• Negative Sentiment: Several executives, including the CEO, CFO, EVP and chief accounting officer, sold shares. The transactions reduced their holdings, but were conducted under pre-arranged Rule 10b5-1 plans and were intended to cover tax obligations on vested equity awards, making them a relatively weak bearish signal.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new position in Tempus AI in the 4th quarter worth about $27,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI during the third quarter worth approximately $38,000. EMC Capital Management purchased a new position in Tempus AI during the second quarter worth approximately $29,000. Finally, Danske Bank A S acquired a new stake in Tempus AI in the third quarter valued at approximately $48,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

The company has a market capitalization of $13.03 billion, a price-to-earnings ratio of -50.15 and a beta of 3.58. The firm has a fifty day simple moving average of $52.44 and a 200 day simple moving average of $51.21. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same period in the prior year, the company posted ($0.22) EPS. The business’s quarterly revenue was up 21.6% on a year-over-year basis. On average, analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.